Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

Abstract

Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. Pralatrexate was US FDA approved for the treatment of relapsed/refractory peripheral T-cell lymphoma in 2009. Approval was based on data from the PROPEL trial that demonstrated an overall response rate of 29% in a heavily pretreated patient population. The dose and schedule of pralatrexate is 30-mg/m(2) weekly for 6 weeks, given in 7-week cycles. Folate and vitamin B12 supplementation are required to minimize toxicity. The most common toxicities are mucositis, thrombocytopenia, nausea and fatigue.

• Authors: Terri Parker, Lisa Barbarotta, Francine Foss
• Journal: Future oncology (London, England) (Future Oncol) Vol. 9 Issue 1 Pg. 21-9 (Jan 2013) ISSN: 1744-8301 [Electronic] England
• PMID: 23252560 (Publication Type: Journal Article, Review)

Chemical References

• 10-propargyl-10-deazaaminopterin
• Antineoplastic Agents
• Aminopterin

Topics

• Aminopterin (adverse effects, analogs & derivatives, chemistry, pharmacokinetics, therapeutic use)
• Animals
• Antineoplastic Agents (adverse effects, chemistry, pharmacokinetics, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Drug Evaluation, Preclinical
• Humans
• Lymphoma, T-Cell (drug therapy)
• Recurrence